Recent progress in mesenchymal stem cell-based therapy for acute lung injury

Area of Science:

• Regenerative Medicine
• Pulmonology
• Critical Care Medicine

Background:

• Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are critical conditions with limited effective treatments.
• Mesenchymal stem cells (MSCs) are being investigated as a novel therapeutic approach for ALI/ARDS.
• Extensive preclinical research has explored MSC efficacy and mechanisms in ALI animal models.

Purpose of the Study:

• To review recent advancements in MSC-based therapies for ALI.
• To summarize findings from preclinical studies and clinical trials of MSCs in ALI treatment.
• To elucidate the underlying mechanisms of MSC action in ALI/ARDS.

Main Methods:

• Review of preclinical studies on MSCs in ALI animal models.
• Analysis of recent clinical trials investigating MSC treatment for ALI/ARDS.
• Examination of the therapeutic mechanisms of MSCs in lung injury.

Main Results:

• MSCs derived from various sources demonstrate therapeutic effects in preclinical ALI models.
• Clinical trials, particularly for COVID-19-related lung injury, show promising results for MSC therapy.
• The potential of MSCs in combating COVID-19-induced ALI/ARDS is increasingly recognized.

Conclusions:

• MSC-based therapy is a promising strategy for treating ALI/ARDS.
• Further research and clinical trials are warranted to optimize MSC application.
• Understanding MSC mechanisms is crucial for developing effective treatments for lung injury.